Marker Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	14.92	16.07	19.19	15.11	11.78	42.35
Cash & Short-Term Investments	14.92	16.07	19.19	15.11	11.78	42.35
Cash Growth	8.93%	-16.28%	27.01%	28.26%	-72.18%	98.34%
Other Receivables	1.38	1.37	2.35	1.03	2.4	0
Total Trade Receivables	1.38	1.37	2.35	1.03	2.4	0
Other Current Assets	1.14	1.63	0.48	0.99	2.44	3.63
Total Current Assets	17.43	19.07	22.02	17.13	16.62	45.98
Net Property, Plant & Equipment	-	-	-	-	-	22.15
Other Long-Term Assets	-	-	-	-	17.8	-
Total Assets	17.43	19.07	22.02	17.13	34.42	68.14
Accounts Payable	1.91	1.3	1.75	1.75	2.52	11.13
Current Portion of Leases	-	-	-	-	-	0.62
Unearned Revenue	0.72	0.97	-	-	-	1.15
Other Current Liabilities	1	-	1.71	1.33	5.26	-
Total Current Liabilities	3.64	2.27	3.46	3.07	7.78	12.9
Long-Term Leases	-	-	-	-	-	11.25
Other Long-Term Liabilities	-	-	-	-	7.04	-
Total Long-Term Liabilities	-	-	-	-	7.04	11.25
Total Liabilities	3.64	2.27	3.46	3.07	14.82	24.15
Common Stock	0.02	0.02	0.01	0.01	0.01	0.01
Additional Paid-in Capital	476.14	475.96	465.57	450.33	447.64	442.1
Retained Earnings	-462.36	-459.18	-447.02	-436.29	-428.05	-398.12
Shareholders' Equity	13.8	16.8	18.56	14.05	19.6	43.99
Total Liabilities & Equity	17.43	19.07	22.02	17.13	34.42	68.14
Total Debt	-	0	0	0	0	11.87
Net Cash (Debt)	14.92	16.07	19.19	15.11	11.78	30.48
Net Cash Growth	-7.17%	-16.28%	27.01%	28.26%	-61.35%	235.15%
Net Cash Per Share	0.86	1.05	2.14	1.72	1.41	3.98
Book Value	13.8	16.8	18.56	14.05	19.6	43.99
Book Value Per Share	0.80	1.10	2.07	1.60	2.35	5.75
Tangible Book Value	13.8	16.8	18.56	14.05	19.6	43.99
Tangible Book Value Per Share	0.80	1.10	2.07	1.60	2.35	5.75

SEC Filings: 10-K · 10-Q